# US 2019/0375799 A1 · Polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375799 A1
- Document ID: US20190375799A1
- Status: Published application
- Kind: A1
- Application number: 16/406,415
- Filed: 2019-05-08
- Published: 2019-12-12
- Earliest claimed: 2010-07-09
- Assignees: Affibody AB
- Applicants: Affibody AB
- Inventors: Caroline Ekblad; Lars Abrahmsen
- Web page: https://patentgrep.com/patent/US20190375799A1

## CPC

- C07K 14/315: from Streptococcus (G), e.g. Enterococci
- A61K 51/081: {the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/001: {by chemical synthesis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/21: containing a His-tag
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K 2319/50: containing protease site
- C07K 2319/70: containing domain for protein-protein interaction
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. It also relates to new methods and uses that exploit binding by these and other compounds to albumin in different contexts, some of which have significance for treatment or diagnosis of disease in mammals including humans.

## Claims

### Claim at position 1

1-84. (canceled)

### Claim 85

An albumin binding polypeptide comprising an amino acid sequence selected from:
i)
(SEQ ID NO: 204)
LAX3AKX6X7ANX10ELDX14YGVSDFYKRLIX26KAKTVEGVEALKX39X40
ILX43X44LP
wherein independently of each other
X3 is selected from E, S, Q and C;
X6 is selected from E, S and C;
X7 is selected from A and S;
X10 is selected from A, S and R;
X14 is selected from A, S, C and K;
X26 is selected from D and E;
X39 is selected from D and E;
X40 is selected from A and E;
X43 is selected from A and K;
X44 is selected from A, S and E;
L in position 45 is present or absent; and
P in position 46 is present or absent; and
ii) an amino acid sequence which has at least 95% identity to the sequence defined in i), provided that X7 is neither L, E nor D.

### Claim 86 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X6 is E.

### Claim 87 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X3 is S.

### Claim 88 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X3 is E.

### Claim 89 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X7 is A.

### Claim 90 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X14 is S.

### Claim 91 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X14 is C.

### Claim 92 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X10 is A.

### Claim 93 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X10 is S.

### Claim 94 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X26 is D.

### Claim 95 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X26 is E.

### Claim 96 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X39 is D.

### Claim 97 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X39 is E.

### Claim 98 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X40 is A.

### Claim 99 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X43 is A.

### Claim 100 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X44 is A.

### Claim 101 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein X44 is S.

### Claim 102 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein L in position 45 is present.

### Claim 103 (depends on 85)

The albumin binding polypeptide according to claim 85, wherein P in position 46 is present.

### Claim 104 (depends on 85)

The albumin binding polypeptide according to claim 85, which binds to albumin such that the koff value of the interaction is at most 5×10−5 s−1.

### Claim 105 (depends on 104)

The albumin binding polypeptide according to claim 104, which binds to albumin such that the koff value of the interaction is at most 5×10−6 s−1.

### Claim 106 (depends on 85)

The albumin binding polypeptide according to claim 85, whose amino acid sequence is selected from any one of SEQ ID NO:1-144 and SEQ ID NO:164-203.

### Claim 107 (depends on 106)

The albumin binding polypeptide according to claim 106, whose amino acid sequence is selected from any one of SEQ ID NO:4-5, SEQ ID NO:7-8, SEQ ID NO:10-11, SEQ ID NO:13-14, SEQ ID NO:16-17, SEQ ID NO:19-20, SEQ ID NO:22-23, SEQ ID NO:25-26, SEQ ID NO:28-29, SEQ ID NO:31-32, SEQ ID NO:34-35, SEQ ID NO:37-38, SEQ ID NO:41-42, SEQ ID NO:49-50, SEQ ID NO:164-170 and SEQ ID NO:192-203.

### Claim 108 (depends on 106)

The albumin binding polypeptide according to claim 106, whose amino acid sequence is selected from any one of SEQ ID NO:1-144.

### Claim 109 (depends on 108)

The albumin binding polypeptide according to claim 108, whose amino acid sequence is selected from any one of SEQ ID NO:4-5, SEQ ID NO:7-8, SEQ ID NO:10-11, SEQ ID NO:13-14, SEQ ID NO:16-17, SEQ ID NO:19-20, SEQ ID NO:22-23, SEQ ID NO:25-26, SEQ ID NO:28-29, SEQ ID NO:31-32, SEQ ID NO:34-35, SEQ ID NO:37-38, SEQ ID NO:41-42 and SEQ ID NO:49-50.

### Claim 110 (depends on 85)

The albumin binding polypeptide according to claim 85, further comprising one or more additional amino acid residues positioned at the N- and/or the C-terminal of the sequence defined in i).

### Claim 111 (depends on 110)

The albumin binding polypeptide according to claim 110, in which the additional amino acids comprise at least one serine residue at the N-terminal of the polypeptide.

### Claim 112 (depends on 110)

The albumin binding polypeptide according to claim 110, in which the additional amino acids comprise a glycine residue at the N-terminal of the polypeptide.

### Claim 113 (depends on 110)

The albumin binding polypeptide according to claim 110, in which the additional amino acids comprise a cysteine residue at the N-terminal of the polypeptide.

### Claim 114 (depends on 110)

The albumin binding polypeptide according to claim 110, in which the additional amino acids comprise a lysine residue at the C-terminal of the polypeptide.

### Claim 115 (depends on 110)

The albumin binding polypeptide according to claim 110, in which the additional amino acids comprise a glycine residue at the C-terminal of the polypeptide.

### Claim 116 (depends on 110)

The albumin binding polypeptide according to claim 110, in which the additional amino acids comprise a cysteine residue at the C-terminal of the polypeptide.

### Claim 117 (depends on 110)

The albumin binding polypeptide according to claim 110, whose amino acid sequence is selected from any one of SEQ ID NO:145-150 and SEQ ID NO:162-163.

### Claim 118 (depends on 85)

The albumin binding polypeptide according to claim 85, comprising no more than two cysteine residues.

### Claim 119 (depends on 118)

The albumin binding polypeptide according to claim 118, comprising no more than one cysteine residue.

### Claim 120 (depends on 85)

The albumin binding polypeptide according to claim 85, which binds to human serum albumin.

### Claim 121 (depends on 85)

A fusion protein or conjugate comprising
i) a first moiety consisting of the albumin binding polypeptide according to claim 85; and
ii) a second moiety consisting of a polypeptide having a desired biological activity.

### Claim 122 (depends on 121)

The fusion protein or conjugate according to claim 121, in which the second moiety having a desired biological activity is a therapeutically active polypeptide.

### Claim 123 (depends on 122)

The fusion protein or conjugate according to claim 122, in which the second moiety having a desired biological activity is selected from the group consisting of human endogenous enzymes, hormones, growth factors, chemokines, cytokines and lymphokines.

### Claim 124 (depends on 123)

The fusion protein or conjugate according to claim 123, in which the second moiety is selected from the group consisting of interleukin-2 (IL-2), glucagon-like peptide 1 (GLP-1), brain natriuretic peptide (BNP), interleukin-1 receptor antagonist (IL-1-RA), keratinocyte growth factor (KGF), ancestim, growth hormone (GH), granulocyte-colony stimulating factor (G-CSF), cytotoxic T lymphocyte-associated protein 4 (CTLA-4), myostatin, Factor VII, Factor VIII and Factor IX.

### Claim 125 (depends on 122)

The fusion protein or conjugate according to claim 122, in which the second moiety having a desired biological activity is a non-human biologically active protein, selected from the group consisting of bacterial toxins, enzymes and activating proteins.

### Claim 126 (depends on 121)

The fusion protein or conjugate according to claim 121, in which the second moiety having a desired biological activity is a binding polypeptide capable of selective interaction with a target molecule.

### Claim 127 (depends on 126)

The fusion protein or conjugate according to claim 126, in which the binding polypeptide is selected from the group consisting of antibodies and fragments and domains thereof substantially retaining antibody binding activity; microbodies, maxybodies, avimers, other small disulfide-bonded proteins; binding proteins derived from a scaffold selected from the group consisting of staphylococcal protein A and domains thereof, other three helix domains, lipocalins, ankyrin repeat domains, cellulose binding domains, y crystallines, green fluorescent protein, human cytotoxic T lymphocyte-associated antigen 4, protease inhibitors, Kunitz domains, PDZ domains, SH3 domains, peptide aptamers, staphylococcal nuclease, tendamistats, fibronectin type III domain, transferrin, zinc fingers and conotoxins.

### Claim 128 (depends on 127)

The fusion protein or conjugate according to claim 127, in which said target molecule is selected from the group consisting of amyloid B (AB) peptide of Alzheimer's disease; other disease-associated amyloid peptides; toxins, bacterial toxins, snake venoms; blood clotting factors, von Willebrand factor; interleukins, interleukin-13 (IL-13); myostatin; pro-inflammatory factors, tumor necrosis factor alpha (TNF-α), TNF-α receptor, IL-1, IL-23 and IL-8; complement factors, complement component 3 (C3), C5; hypersensitivity mediators, histamine, immunoglobulin E (IgE); tumor-related antigens, cluster of differentiation molecule 19 (CD19), CD20, CD22, CD30, CD33, CD40, CD52, CD70, oncogene MET (cMet), epidermal growth factor receptor 1 (HER1), HER2, HER3, HER4, carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), IL-2 receptor, mucin 1 (MUC1), prostate-specific membrane antigen (PSMA), tumor-associated glycoprotein 72 (TAG-72), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), growth hormone (GH), insulin and somatostatin.

### Claim 129 (depends on 121)

The fusion protein or conjugate according to claim 121, comprising a further moiety consisting of a polypeptide having a further, desired biological activity, which may be the same as or different from that of the second moiety.

### Claim 130 (depends on 129)

The fusion protein or conjugate according to claim 129, wherein the second moiety is a therapeutically active polypeptide, and the further moiety is a binding polypeptide capable of selective interaction with a target molecule.

### Claim 131 (depends on 121)

The fusion protein or conjugate according to claim 121, in which the second moiety is conjugated to the albumin binding polypeptide via the thiol group of any cysteine residue present at position X14 of the polypeptide.

### Claim 132 (depends on 85)

The albumin binding polypeptide according to claim 85, further comprising a cytotoxic agent.

### Claim 133 (depends on 132)

The albumin binding polypeptide according to claim 132, wherein the cytotoxic agent is selected from calicheamycin, auristatin, doxorubicin, maytansinoid, taxol, ecteinascidin, geldanamycin, methotrexate and their derivatives, and combinations thereof.

### Claim 134 (depends on 85)

The albumin binding polypeptide according to claim 85 further comprising a label.

### Claim 135 (depends on 134)

The albumin binding polypeptide according to claim 134, in which said label is selected from the group consisting of fluorescent dyes and metals, chromophoric dyes, chemiluminescent compounds and bioluminescent proteins, enzymes, radionuclides and particles.

### Claim 136 (depends on 135)

The albumin binding polypeptide according to claim 135, comprising a chelating environment provided by a polyaminopolycarboxylate chelator conjugated to the albumin binding polypeptide via a thiol group of a cysteine residue or an amine group of a lysine residue.

### Claim 137 (depends on 136)

The albumin binding polypeptide according to claim 136, wherein the polyaminopolycarboxylate chelator is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid or a derivative thereof.

### Claim 138 (depends on 137)

The albumin binding polypeptide according to claim 137, wherein the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid derivative is 1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide.

### Claim 139 (depends on 136)

The albumin binding polypeptide according to claim 136, wherein the polyaminopolycarboxylate chelator is diethylenetriaminepentaacetic acid or derivatives thereof.

### Claim 140 (depends on 85)

A polynucleotide encoding the albumin binding polypeptide according to claim 85.

### Claim 141 (depends on 140)

A method of producing a polypeptide, comprising expressing the polynucleotide according to claim 140.

### Claim 142 (depends on 140)

An expression vector comprising the polynucleotide according to claim 140.

### Claim 143 (depends on 142)

A host cell comprising the expression vector according to claim 142.

### Claim 144 (depends on 85)

A method of producing the albumin binding polypeptide according to claim 85 by non-biological peptide synthesis using amino acids and/or amino acid derivatives having protected reactive side-chains, the non-biological peptide synthesis comprising
step-wise coupling of the amino acids and/or the amino acid derivatives to form the albumin binding polypeptide;
deprotecting the protected reactive side-chains of the albumin binding polypeptide; and
folding of the albumin binding polypeptide in aqueous solution.

### Claim 145 (depends on 144)

The method of producing a polypeptide according to claim 144, further comprising
conjugating the albumin binding polypeptide with a therapeutically active polypeptide.

### Claim 146 (depends on 121)

The fusion protein or conjugate according to claim 121, further comprising a cytotoxic agent.

### Claim 147 (depends on 146)

The fusion protein or conjugate according to claim 146, wherein the cytotoxic agent is selected from calicheamycin, auristatin, doxorubicin, maytansinoid, taxol, ecteinascidin, geldanamycin, methotrexate and their derivatives, and combinations thereof.

### Claim 148 (depends on 121)

The fusion protein or conjugate according to claim 121 further comprising a label.

### Claim 149 (depends on 148)

The fusion protein or conjugate according to claim 148, in which said label is selected from the group consisting of fluorescent dyes and metals, chromophoric dyes, chemiluminescent compounds and bioluminescent proteins, enzymes, radionuclides and particles.

### Claim 150 (depends on 149)

The fusion protein or conjugate according to claim 149, comprising a chelating environment provided by a polyaminopolycarboxylate chelator conjugated to the albumin binding polypeptide via a thiol group of a cysteine residue or an amine group of a lysine residue.

### Claim 151 (depends on 150)

The fusion protein or conjugate according to claim 150, wherein the polyaminopolycarboxylate chelator is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid or a derivative thereof.

### Claim 152 (depends on 151)

The fusion protein or conjugate according to claim 151, wherein the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid derivative is 1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide.

### Claim 153 (depends on 150)

The fusion protein or conjugate according to claim 150, wherein the polyaminopolycarboxylate chelator is diethylenetriaminepentaacetic acid or derivatives thereof.

### Claim 154 (depends on 121)

A polynucleotide encoding the fusion protein according to claim 121.

### Claim 155 (depends on 154)

A method of producing a polypeptide, comprising expressing the polynucleotide according to claim 154.

### Claim 156 (depends on 154)

An expression vector comprising the polynucleotide according to claim 154.

### Claim 157 (depends on 156)

A host cell comprising the expression vector according to claim 156.
